A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Neratinib (Primary) ; Temsirolimus (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Puma Biotechnology
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2016 Status changed from active, no longer recruiting to completed.
- 11 May 2016 This trial was completed in Spain according to European Clinical Trials Database.